support:13376277882 | tech@naturebios.com

PD-L1/CD274 Rabbit mAb [CG95]Cat NO.: A29269

Western blot(SDS PAGE) analysis of extracts from U-87MG cells.Using PD-L1/CD274 Rabbit mAb [CG95] at dilution of 1:1000 incubated at 4℃ over night.

  • SizePriceIn stock
  • 50ul1280咨询客服
  • 100ul2380咨询客服
Order Datasheet

Product information

Protein names :CD274,B7H1,PDCD1L1,PDCD1LG1,PDL1,PD1L1_HUMAN,Programmed cell death 1 ligand 1

UniProtID :Q9NZQ7

MASS(da) :33,275

MW(kDa) :50

Form :Liquid

Purification :Protein A purification

Host :Rabbit

Isotype :IgG

sensitivity :Endogenous

Reactivity :Human,Mouse,Rat

  • ApplicationDilution
  • 免疫印迹(WB)1:1000-2000,
  • 免疫组化(IHC)1:100
  • The optimal dilutions should be determined by the end user

Specificity :Antibody is produced by immunizing animals with a synthetic peptide at the sequence of human PD-L1/CD274.

Storage :Antibody store in 10 mM PBS, 0.5mg/ml BSA, 150% glycerol. Shipped at 4°C. Store at-20°C or -80°C. Products are valid for one natural year of receipt.Avoid repeated freeze / thaw cycles.

WB Positive detected :U-87MG cells

Function : Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813417, PubMed:28813410). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813417, PubMed:28813410). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077).., The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813417, PubMed:28813410). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity)..

Tissue specificity :Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes..

Subcellular locationi :Cell membrane,Single-pass type I membrane protein. Early endosome membrane,Single-pass type I membrane protein. Recycling endosome membrane,Single-pass type I membrane protein.

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 1% w/v BSA, 1X TBST at 4°C overnight.